Co-crystallizing the NEPi sacubitril with the angiotensin II type 1 receptor blocker, valsartan, in a one-to-one molar ratio as LCZ696, jointly termed an angiotensin receptor-neprilysin inhibitor (ARNI), was more successful than valsartan in reducing diastolic blood pressure in hypertensive patients, with no reports of angioedema.106 The rationale was to avoid the double hit on bradykinin breakdown and angioedema by blocking angiotensin II type 1 receptors rather than inhibiting ACE. Here, ACE is linked to angioedema.